E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with V
>
Issuers starting with V, BK only
>
All stories on Vertex Pharmaceuticals Inc.
>
Stories on Vertex Pharmaceuticals Inc., BK only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Vertex Pharmaceuticals Inc.
7/5/2022
BK
Vertex Pharmaceuticals enters $500 million five-year senior revolver
9/21/2020
BK
Vertex Pharmaceuticals enters into $2 billion two-year revolver
9/17/2019
BK
Vertex Pharmaceuticals enters into $500 million five-year revolver
10/17/2016
BK
Vertex Pharmaceuticals closes $500 million five-year revolver
10/27/2015
BK
Vertex Pharmaceuticals amends credit facility repayment schedule
7/9/2014
BK
Vertex Pharmaceuticals gets $300 million term loan at 7.2% initial rate
1/13/2011
BK
Vertex Pharmaceuticals adds $100 million undrawn revolver via BofA
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
